Abstract
Background Epstein Barr virus (EBV)-associated endemic Burkitt’s Lymphoma pediatric cancer is associated with morbidity and mortality among children resident in holoendemic Plasmodium falciparum regions in western Kenya. P. falciparum exerts strong selection pressure on sickle cell trait (SCT), alpha thalassemia (-α3.7/αα), glucose-6-phosphate dehydrogenase (G6PD), and merozoite surface protein 2 (MSP-2) variants (FC27, 3D7) that confer reduced malarial disease severity. The current study tested the hypothesis that SCT, (-α3.7/αα), G6PD mutation and (MSP-2) variants (FC27, 3D7) are associated with an early age of EBV acquisition.
Methods Data on infant EBV infection status ( T) (OR = 2.614, P = 0.212)] and [Union (1360 C > T)/Kaiping (1388G > A) (OR = 0.321, P = 0.295)]. There was no relationship between EBV acquisition and in-utero exposure to either FC27 (OR = 0.922, P = 0.914) or 3D7 (OR = 0.933, P = 0.921). In addition, EBV acquisition in infants ≥ 6–12 months also showed no association with -α3.7/αα (OR = 0.681, P = 0.442), SCT (OR = 0.513, P = 0.305), G6PD [(Viangchan (871G > A)/Chinese (1024 C > T) (OR = 0.640, P = 0.677)], [Mahidol (487G > A)/Coimbra (592 C > T) (OR = 0.948, P = 0.940)], [(Union (1360 C > T)/Kaiping (1388G > A) (OR = 1.221, P = 0.768)], African A (OR = 0.278, P = 0.257)], or in utero exposure to either FC27 (OR = 0.780, P = 0.662) or 3D7 (OR = 0.549, P = 0.241).
Conclusion Although hemoglobinopathies (-α3.7/αα, SCT, and G6PD mutations) and in-utero exposure to MSP-2 were not associated with EBV acquisition in infants 0–12 months, novel G6PD variants were discovered in the population from western Kenya. To establish that the known and novel hemoglobinopathies, and in utero MSP-2 exposure do not confer susceptibility to EBV, future studies with larger sample sizes from multiple sites adopting genome-wide analysis are required.
K., O (2024). Human NCR3 gene variants rs2736191 and rs11575837 alter longitudinal risk for development of pediatric malaria episodes and severe malarial anemia. Afribary. Retrieved from https://tracking.afribary.com/works/human-ncr3-gene-variants-rs2736191-and-rs11575837-alter-longitudinal-risk-for-development-of-pediatric-malaria-episodes-and-severe-malarial-anemia
K., Olewe "Human NCR3 gene variants rs2736191 and rs11575837 alter longitudinal risk for development of pediatric malaria episodes and severe malarial anemia" Afribary. Afribary, 04 Jun. 2024, https://tracking.afribary.com/works/human-ncr3-gene-variants-rs2736191-and-rs11575837-alter-longitudinal-risk-for-development-of-pediatric-malaria-episodes-and-severe-malarial-anemia. Accessed 14 Nov. 2024.
K., Olewe . "Human NCR3 gene variants rs2736191 and rs11575837 alter longitudinal risk for development of pediatric malaria episodes and severe malarial anemia". Afribary, Afribary, 04 Jun. 2024. Web. 14 Nov. 2024. < https://tracking.afribary.com/works/human-ncr3-gene-variants-rs2736191-and-rs11575837-alter-longitudinal-risk-for-development-of-pediatric-malaria-episodes-and-severe-malarial-anemia >.
K., Olewe . "Human NCR3 gene variants rs2736191 and rs11575837 alter longitudinal risk for development of pediatric malaria episodes and severe malarial anemia" Afribary (2024). Accessed November 14, 2024. https://tracking.afribary.com/works/human-ncr3-gene-variants-rs2736191-and-rs11575837-alter-longitudinal-risk-for-development-of-pediatric-malaria-episodes-and-severe-malarial-anemia